OpenScience.ink

1 week ago • The International journal of eating disorders

Eating Disorder Risk and Screening in Patients Using GLP-1 Receptor Agonists Compared to Weight Loss SurgeryEating Disorder Risk and Screening in Patients Using GLP-1RAs: Lessons Learned From Metabolic and Bariatric Surgery.

1 week ago • International journal of cardiology. Cardiovascular risk and prevention

Comparing combined GLP-1 and SGLT2 treatments to GLP-1 alone for heart rhythm issues in non-diabetic obese patients over timeCombination GLP-1 receptor agonist and SGLT2 inhibitor therapy versus GLP-1 receptor agonist monotherapy on arrhythmia outcomes in non-diabetic obese patients: A real-world time-dependent analysis.

📖 Top 30% Journal

1 week ago • Frontiers in microbiology

How Tirzepatide May Affect Gut Bacteria and Metabolism in Obesity TreatmentTirzepatide and the gut microbiota-obesity axis: metabolic mechanisms and therapeutic perspectives.

📖 Top 20% Journal

1 week ago • Medicine

Semaglutide's effects on fatty liver disease and liver inflammation linked to metabolism: Review and analysis of placebo-controlled trialsTherapeutic role of semaglutide in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis of placebo-controlled trials with GRADE evidence assessment.

📖 Top 50% Journal

1 week ago • Integrative medicine research

Chinese herbal medicine versus liraglutide for weight loss in adults with obesity over 12 monthsComparative effectiveness of Chinese herbal medicine versus liraglutide for weight loss in adults with obesity: A 12-month real-world target trial emulation study.

📖 Top 50% Journal

1 week ago • Journal of diabetes investigation

Differences between liraglutide and dulaglutide in causing or worsening eye and kidney problemsComparison between liraglutide and dulaglutide on the incidence or progression of eye and kidney complications.

📖 Top 20% Journal

1 week ago • Nature metabolism

Different brain areas control eating when GIP receptors are activated or blockedDistinct brain regions mediate regulation of food intake in response to GIPR agonism or antagonism.

🥇 Top 1% Journal

1 week ago • Chronic diseases and translational medicine

How GLP-1 Receptor Agonists Relate to Stomach Emptying, Aspiration Risk, and Current Guidelines for EndoscopyGLP-1 Receptor Agonists and Endoscopy: Understanding Gastric Stasis, Aspiration Risk, and Contemporary Peri-Procedural Guidance.

1 week ago • Frontiers in endocrinology

Monoclonal antibody treatments for diabetic kidney disease: from how they work to clinical resultsTherapeutic monoclonal antibodies for diabetic kidney disease: a narrative review from basic mechanisms to clinical evidence.

🎖️ Top 10% Journal

1 week ago • Kidney international

Different Kidney Benefits of GLP-1 Drugs in People with Type 2 DiabetesHeterogeneous Treatment Effects of GLP-1RA on Kidney Outcomes in Patients with Type 2 Diabetes.

🥈 Top 2% Journal

1 week ago • Diabetes

GIP Quickly Reduces Muscle Blood Flow Increases Caused by Insulin and GLP-1GIP Acutely Blunts Insulin- and GLP-1-Induced Muscle Microvascular Perfusion.

🥉 Top 5% Journal

1 week ago • ASAIO journal (American Society for Artificial Internal Organs : 1992)

Effects of Glucagon-like Peptide-1 Receptor Agonists in Obese Patients with Heart PumpsGlucagon-like Peptide-1 Receptor Agonists in Obese Left Ventricular Assist Device Recipients: A Propensity-Matched Real-World Cohort Study.

📖 Top 20% Journal

1 week ago • Cureus

Cardiovascular benefits of semaglutide 2.4 mg in people with overweight or obesity: a review of current evidenceEvaluating the Cardiovascular Benefits of Innovator Semaglutide 2.4 mg (Recombinant DNA (r-DNA)) in Patients With Overweight or Obesity: A Critical Review of Current Evidence.

1 week ago • BMJ open

Availability, cost, and affordability of two diabetes treatments in 10 countriesAvailability, treatment costs and affordability of SGLT-2 inhibitors and GLP-1 RAs for diabetes in 10 countries: a cross-sectional study.

📖 Top 20% Journal

1 week ago • Obesity pillars

Primary Care Doctors' Opinions on Helping Patients Who Lose Insurance for Weight-Loss Drugs Based on Glucagon-Like Peptide-1A survey of primary care physicians' views on supporting patients who lose insurance coverage for Glucagon-Like Peptide-1-based drugs for weight management.

📖 Top 20% Journal

1 week ago • Singapore medical journal

Recent progress and future directions in managing diabetic kidney diseaseRapidly changing landscape of diabetic kidney disease management: recent advances and the road ahead.

1 week ago • Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology

Comparing lifestyle changes, surgery, and semaglutide for weight control in endometrial cancerComparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.

📖 Top 50% Journal

1 week ago • The Journal of biological chemistry

A sensor system for live, detailed detection of PYY hormone release from gut hormone-producing cellsA biosensor platform for scalable and live detection of PYY hormone production from enteroendocrine cells with single-event resolution.

🎖️ Top 10% Journal

1 week ago • Cureus

Effectiveness and safety of weekly semaglutide compared to daily insulin and similar drugs in adults with type 2 diabetes not controlled by oral medicationsEfficacy and Safety of Once-Weekly Semaglutide Versus Basal Insulin and Other GLP-1 Receptor Agonists in Adults With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs: A Systematic Review and Pairwise Meta-Analysis.

1 week ago • JAMA network open

Glucagon-Like Peptide-1 Drugs and Risk of Fragile Bone Fractures in Type 2 DiabetesGlucagon-Like Peptide-1 Receptor Agonists and Fragility Fracture Risk in Type 2 Diabetes.

🥈 Top 2% Journal

1 week ago • Schizophrenia research

Effects of diabetes-related drugs on metabolism in schizophrenia patients taking antipsychoticsEffects of glucagon-like peptide-1 receptor agonists on metabolic outcomes in antipsychotic-treated patients with schizophrenia: A systematic review and meta-analysis.

📖 Top 20% Journal

1 week ago • Medicines (Basel, Switzerland)

Early Real-World Results of Semaglutide for Obesity Beyond Just Weight LossBeyond Weight Loss: Early Real-World Evidence of Semaglutide in Obesity.

1 week ago • BMJ open

Semaglutide to prevent type 2 diabetes in women with early diabetes risk after pregnancy diabetes: plan for a Belgian double-blind placebo-controlled trialSemaglutide for prevention of type 2 diabetes in women with postpartum prediabetes after gestational diabetes: protocol for a Belgian multicentre double-blind randomised placebo-controlled trial.

📖 Top 20% Journal

1 week ago • Cardiology in review

Different Effects of Two Diabetes Drugs Added After Heart Surgery on Patient OutcomesDifferential Effects of GLP-1 Receptor Agonist and SGLT2 Inhibitor Add-on Therapy on Outcomes Following Cardiac Surgery: A Propensity Score-Matched Analysis.

📖 Top 50% Journal

1 week ago • Frontiers in endocrinology

Tirzepatide's effects on body weight and body fat in adults with overweight and obesityEffects of tirzepatide therapy on body weight and body composition in adults with overweight and obesity.

🎖️ Top 10% Journal

1 week ago • Cureus

Weight Loss After Liraglutide Treatment in a Patient with Smith-Magenis SyndromeWeight Loss Following Liraglutide Therapy in a Patient With Smith-Magenis Syndrome: A Case Report.

1 week ago • Endocrinology, diabetes & metabolism

Metabolic and blood sugar effects of Orforglipron, a GLP-1 receptor drug, in adults with and without diabetes: A combined analysis of clinical trialsMetabolic and Glycemic Effects of Orforglipron, a GLP-1 Receptor Agonist, in Adults With or Without Diabetes: A Network Meta-Analysis of Randomised Clinical Trials.

📖 Top 20% Journal

1 week ago • Frontiers in endocrinology

Comparing effects of GLP-1 receptor drugs, metformin, and inositol on body measurements and metabolism in women with polycystic ovary syndromeComparative analysis of glucagon-like peptide-1 receptor agonists, metformin, and inositol in improving anthropometric and metabolic outcomes in women with polycystic ovary syndrome: a network meta-analysis.

🎖️ Top 10% Journal

1 week ago • Endocrinology, diabetes & metabolism

Effectiveness and safety of Tirzepatide for obesity in Asian and non-Asian adults without diabetesComparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis.

📖 Top 20% Journal

1 week ago • Journal of the Endocrine Society

Can genetic differences in GLP-1 and GIP receptors affect response to incretin therapy?Personalization of incretin therapy: can GLP-1 and GIP receptor polymorphisms influence therapy response?

📖 Top 20% Journal

← prevpage 6 of 14next →

Latest GLP-1 Therapies Research Papers